# A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

> **NCT04384666** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
- **OTHER:** Neupro 4 mg / 24 Hr. Transdermal Patch

## Key facts

- **NCT ID:** NCT04384666
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-02
- **Primary completion:** 2020-08-05
- **Final completion:** 2020-08-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04384666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04384666, "A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04384666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*